URGN:NASDAQUroGen Pharma Ltd. Analysis
Data as of 2026-09-01 - not real-time
$43.09
Latest Price
9/10Risk
Risk Level: High
Executive Summary
The moving-average structure behind UroGen Pharma Ltd. is bullish at $43.09, with short-term averages leading the long-term ones. It has gained 4.8% over the past 30 days. With RSI at 44.4 the momentum picture is neutral, alongside a bearish MACD signal. Watch $38.81 as support and $50.81 as the nearer resistance level.
Valuation screens as undervalued: a P/E of 15.4 sits below the sector average of 30.4. Analyst price targets sit 39.2% above the current price. Revenue is growing at 199.2% on a -51.7% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 65.3%, a beta of 1.18 and a maximum drawdown of 42.2%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 3 out of 10.
Valuation screens as undervalued: a P/E of 15.4 sits below the sector average of 30.4. Analyst price targets sit 39.2% above the current price. Revenue is growing at 199.2% on a -51.7% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 65.3%, a beta of 1.18 and a maximum drawdown of 42.2%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 3 out of 10.
Top Market Events
UroGen Pharma Ltd URGN reports strong Cysview adoption and pipeline progress, while raising full-year operating expense...UroGen Pharma Ltd. reported past second-quarter 2026 results showing sales of US$72.46 million versus US$24.22 million...Yahoo Finance26dUroGen Pharma Ltd. URGN Q2 FY2026 earnings call transcriptURGN delivered a standout Q2 2026, with total...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 3/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 27.87
- MACD momentum is negative
Medium Term
1–3 yearsPositive
Model confidence: 4/10
Key Factors
- Short-term moving averages stacked above long-term ones
- P/E of 15.4 versus sector average of 30.4
- Trading above the 200-day average of 27.87
Long Term
> 3 yearsNeutral
Model confidence: 3/10
Key Factors
- P/E of 15.4 versus sector average of 30.4
- Negative profit margin of -51.7%
- Analyst targets imply +39.2% versus the current price
Key Metrics & Analysis
Financial Health
Revenue Growth199.20%
Profit Margin-51.73%
P/E Ratio15.4
ROA-18.06%
P/B Ratio-15.9
Op. Cash Flow$-158916992
Free Cash Flow$-106975752
Industry P/E30.4
Technical Analysis
TrendBullish
RSI44.4
Support$38.81
Resistance$50.81
MA 20$46.52
MA 50$41.91
MA 200$27.87
MACDBearish
VolumeDecreasing
Fear & Greed Index94.79
Valuation
Target Price$60.00
Upside/Downside39.24%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta1.18
Volatility65.29%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.